Company Ascelia Pharma AB

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:50 2024-04-26 am EDT			5-day change	1st Jan Change
11.16 ^SEK	+5.28%		-15.33%	+231.16%

Apr. 10	Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	CI
Feb. 09	Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.

Number of employees: 13

Managers	Title	Age	Since
Magnus Olafsson Corfitzen CEO	Chief Executive Officer	49	13-12-31
Julie Waras Brogren DFI	Director of Finance/CFO	52	19-12-31
Jennie Wilborgsson CTO	Chief Tech/Sci/R&D Officer	40	21-12-31
Carin Linde CTO	Chief Tech/Sci/R&D Officer	52	18-12-31
Andreas Norlin CTO	Chief Tech/Sci/R&D Officer	54	19-12-31
Marie Källström LAW	General Counsel	58	-

Members of the board	Title	Age	Since
Peter James Arthur Benson CHM	Chairman	69	17-05-31
Niels Mengel BRD	Director/Board Member	76	99-12-31
Anna Helena Wennerström BRD	Director/Board Member	59	16-12-31
Hans Maier BRD	Director/Board Member	69	16-12-31
Lauren Barnes BRD	Director/Board Member	50	20-05-05

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	1,113,431	0	0	74.72 %
Stock B	1	33,757,746	26,055,840 ( 77.18 %)	0

Name	Equities	%	Valuation
Heartcore Capital A/S 14.15 %	4,778,129	14.15 %	4 M kr
Fjärde AP-fonden 8.026 %	2,709,266	8.026 %	2 M kr
Øresund-Healthcare Management A/S 5.245 %	1,770,490	5.245 %	2 M kr
Futur Pension Försäkringsaktiebolag 4.439 %	1,498,412	4.439 %	1 M kr
OstVast Capital Management Ltd. 3.555 %	1,200,000	3.555 %	1 M kr
Unionen (Investment Management) 3.436 %	1,160,000	3.436 %	999 154 kr
NORDNET AB 3.261 %	1,100,814	3.261 %	948 175 kr
SPOGÁRD HOLDING ApS 3.039 %	1,025,743	3.039 %	883 513 kr
FCG Fonder AB 1.666 %	562,569	1.666 %	484 563 kr
Magnus Olafsson Corfitzen 0.9469 %	319,645	0.9469 %	275 323 kr

Ascelia Pharma AB

Hyllie Boulevard 34

215 32, Malmö

+46 7 35 17 91 18

http://www.cmc-contrast.se

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ASCELIA PHARMA AB	+231.16%	34.36M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research